[go: up one dir, main page]

PT2627328T - Combinação de agonistas de serotonina para tratamento de distúrbios do movimento - Google Patents

Combinação de agonistas de serotonina para tratamento de distúrbios do movimento

Info

Publication number
PT2627328T
PT2627328T PT117760710T PT11776071T PT2627328T PT 2627328 T PT2627328 T PT 2627328T PT 117760710 T PT117760710 T PT 117760710T PT 11776071 T PT11776071 T PT 11776071T PT 2627328 T PT2627328 T PT 2627328T
Authority
PT
Portugal
Prior art keywords
combinations
treatment
receptor agonists
movement disorders
serotonin receptor
Prior art date
Application number
PT117760710T
Other languages
English (en)
Inventor
Bondo Hansen John
S Thomsen Mikael
Original Assignee
Contera Pharma Aps
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Contera Pharma Aps filed Critical Contera Pharma Aps
Publication of PT2627328T publication Critical patent/PT2627328T/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/165Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42Oxazoles
    • A61K31/422Oxazoles not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PT117760710T 2010-10-15 2011-10-13 Combinação de agonistas de serotonina para tratamento de distúrbios do movimento PT2627328T (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US39354510P 2010-10-15 2010-10-15
DKPA201070441 2010-10-15
US201161491945P 2011-06-01 2011-06-01

Publications (1)

Publication Number Publication Date
PT2627328T true PT2627328T (pt) 2016-11-23

Family

ID=44883032

Family Applications (1)

Application Number Title Priority Date Filing Date
PT117760710T PT2627328T (pt) 2010-10-15 2011-10-13 Combinação de agonistas de serotonina para tratamento de distúrbios do movimento

Country Status (22)

Country Link
US (2) US9186359B2 (pt)
EP (1) EP2627328B1 (pt)
JP (1) JP5907975B2 (pt)
KR (1) KR101825972B1 (pt)
CN (2) CN105193809B (pt)
AU (1) AU2011316225B2 (pt)
BR (1) BR112013009004B1 (pt)
CA (1) CA2813648C (pt)
CY (1) CY1118314T1 (pt)
DK (1) DK2627328T3 (pt)
ES (1) ES2602973T3 (pt)
HR (1) HRP20161402T1 (pt)
HU (1) HUE031661T2 (pt)
IL (1) IL225758A (pt)
LT (1) LT2627328T (pt)
MX (1) MX353625B (pt)
PL (1) PL2627328T3 (pt)
PT (1) PT2627328T (pt)
RS (1) RS55332B1 (pt)
RU (1) RU2611376C2 (pt)
SI (1) SI2627328T1 (pt)
WO (1) WO2012048710A1 (pt)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2714040A1 (en) * 2011-06-01 2014-04-09 Concit Pharma ApS Combinations of serotonin receptor agonists for treatment of movement disorders
RU2670272C2 (ru) 2012-04-18 2018-10-22 Контера Фарма Апс Пероральная фармацевтическая композиция, подходящая для повышения эффективности лечения двигательных нарушений
RU2014150942A (ru) * 2012-06-11 2016-07-27 Сайкодженикс, Инк. Лечение побочных эффектов в виде моторных и двигательных расстройств, связанных с лечением болезни паркинсона
HUE039750T2 (hu) * 2014-06-26 2019-02-28 Contera Pharma Aps Hidroxi-buspiron mozgászavarok kezelésére
PT3131549T (pt) * 2014-07-09 2018-07-04 Pf Medicament Método para tratar distúrbios do movimento com befiradol
WO2016210431A1 (en) * 2015-06-26 2016-12-29 Wright State University Method of treating sepsis-induced myopathy
US11013830B2 (en) * 2015-11-20 2021-05-25 Institut Pasteur 5-hydroxytryptamine 1B receptor-stimulating agent for enhancing in vivo engraftment potential
US11975104B2 (en) 2016-07-11 2024-05-07 Contera Pharma A/S Pulsatile drug delivery system for treating morning akinesia
WO2020087031A1 (en) 2018-10-26 2020-04-30 The Research Foundation For The State University Of New York Combination serotonin specific reuptake inhibitor and serotonin 1a receptor partial agonist for reducing l-dopa-induced dyskinesia
EP4335504A3 (en) 2018-12-20 2024-05-29 Contera Pharma A/S Treatment of movement disorders
EP4076433A4 (en) * 2019-12-20 2023-09-27 The Jackson Laboratory Molecular targets for addiction
CN112931397B (zh) * 2021-01-25 2024-02-27 江南大学 一种帕金森病动物模型的构建方法
KR20240004942A (ko) * 2021-05-07 2024-01-11 일라이 릴리 앤드 캄파니 2,4,6-트리플루오로-n-[6-(1-메틸-피페리딘-4-카르보닐)-피리딘-2-일]-벤즈아미드헤미숙시네이트의 맛 차폐된 조성물 및 그를 포함하는 경구 붕해 정제
CN114712365B (zh) * 2022-06-07 2022-08-23 山东绿叶制药有限公司 Trk抑制剂在制备治疗迟发性运动障碍药物中的应用

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE759371A (fr) 1969-11-24 1971-05-24 Bristol Myers Co Azaspirodecanediones heterocycliques et procedes pour leur preparation
US3976776A (en) 1972-12-06 1976-08-24 Mead Johnson & Company Tranquilizer process employing N-(heteroarcyclic)piperazinylalkylazaspiroalkanediones
US4166452A (en) 1976-05-03 1979-09-04 Generales Constantine D J Jr Apparatus for testing human responses to stimuli
US4182763A (en) 1978-05-22 1980-01-08 Mead Johnson & Company Buspirone anti-anxiety method
US4356108A (en) 1979-12-20 1982-10-26 The Mead Corporation Encapsulation process
US4265874A (en) 1980-04-25 1981-05-05 Alza Corporation Method of delivering drug with aid of effervescent activity generated in environment of use
US4438119A (en) * 1982-12-23 1984-03-20 Mead Johnson & Company Method for alleviation of extrapyramidal motor disorders
US4640921A (en) 1986-02-04 1987-02-03 Bristol-Myers Treatment of sexual dysfunction with buspirone
US4687772A (en) 1986-10-07 1987-08-18 Bristol-Myers Company Method for improvement of short term memory
US4777173A (en) 1987-03-25 1988-10-11 Bristol-Myers Company Method for treatment of alcohol abuse
US5185329A (en) 1988-08-30 1993-02-09 Bristol-Myers Squibb Company Method for treatment of substance addiction
US6432956B1 (en) 1990-02-12 2002-08-13 William C. Dement Method for treatment of sleep apneas
DK0486666T3 (da) 1990-06-07 1998-03-30 Zeneca Ltd Terapeutisk heterocykliske forbindelser
US5633009A (en) 1990-11-28 1997-05-27 Sano Corporation Transdermal administration of azapirones
US5431922A (en) 1991-03-05 1995-07-11 Bristol-Myers Squibb Company Method for administration of buspirone
GB9209882D0 (en) 1992-05-07 1992-06-24 Glaxo Lab Sa Compositions
US5484788A (en) 1993-03-26 1996-01-16 Beth Israel Hospital Association Buspirone as a systemic immunosuppressant
US5637314A (en) 1995-06-07 1997-06-10 Beth Israel Deaconess Medical Center, Inc. Topical and systemic application of buspirone or derivatives thereof for treating atopic dermatitis
GB9706089D0 (en) * 1997-03-24 1997-05-14 Scherer Ltd R P Pharmaceutical composition
US6150365A (en) 1999-08-05 2000-11-21 Bristol-Myers Squibb Company Anxiety method
GB9928578D0 (en) 1999-12-03 2000-02-02 Zeneca Ltd Pharmaceutical formulations
WO2002044159A2 (en) * 2000-11-29 2002-06-06 Eli Lilly And Company 1-(2-m-methanesulfonamidophenylethyl)-4-(m-trifluoromethylphenyl)piperazine and pharmaceutically acceptable salts and solvates thereof and their use in the treatment of incontinence
WO2002053139A2 (en) 2001-01-05 2002-07-11 Eli Lilly And Company Excitatory amino acid receptor antagonist and 5-ht1f agonist combination: a method for the treatment of neurological disorders
US8329734B2 (en) 2009-07-27 2012-12-11 Afgin Pharma Llc Topical therapy for migraine
US20040235920A1 (en) * 2001-09-12 2004-11-25 Gerd Bartoszyk Novel use of substituted aminomethyl chromans for the treatment of movement disorders and of adverse effects induced by drugs administered to treat extrapyramidal movement disorders
DE10353657A1 (de) 2003-11-17 2005-06-23 Merck Patent Gmbh Indolderivate
US20070173536A1 (en) 2004-02-06 2007-07-26 Ciba Specialty Chemicals Holding Inc. Crystalline forms of zolmitriptan
BRPI0514983A (pt) * 2004-09-07 2008-07-01 Pfizer combinação de um agonista do receptor 5-ht(1) e um ligante alfa-2-delta para tratamento da enxaqueca
US9066903B2 (en) 2006-02-28 2015-06-30 The United States Of America As Represented By The Department Of Veterans Affairs Pharmacological treatment of Parkinson's disease
EP2037964A2 (en) * 2006-06-16 2009-03-25 Solvay Pharmaceuticals B.V. Combination preparations comprising bifeprunox and l-dopa
TW200831479A (en) * 2006-09-26 2008-08-01 Cytrx Corp Pharmaceutical compositions and methods for treating diseases
WO2008047839A1 (en) * 2006-10-19 2008-04-24 Dainippon Sumitomo Pharma Co., Ltd. 5-ht1a receptor agonist
WO2008115797A1 (en) * 2007-03-16 2008-09-25 Pavo, Inc. Therapeutic compositions and methods
WO2009002084A2 (en) 2007-06-27 2008-12-31 Hanmi Pharm. Co., Ltd. Method for preparing rapidly disintegrating formulation for oral administration and apparatus for preparing and packing the same
EP2317996A1 (en) 2008-06-24 2011-05-11 Anders Björklund Eltoprazine for suppression of l-dopa induced dyskinesias
CN102186461A (zh) 2008-10-14 2011-09-14 麦克内尔股份公司 多部分口腔内剂型及其用途
GEP20146013B (en) 2009-01-23 2014-01-27 Aziende Chimiche Riunite Angelini Francesco A C R A F S P A It Controlled release pharmaceutical or food formulation and method of preparation thereof
US8710092B2 (en) 2009-12-23 2014-04-29 Map Pharmaceuticals, Inc. Substituted indolo 4,3 FG quinolines useful for treating migraine
EP2714040A1 (en) 2011-06-01 2014-04-09 Concit Pharma ApS Combinations of serotonin receptor agonists for treatment of movement disorders

Also Published As

Publication number Publication date
BR112013009004B1 (pt) 2022-05-10
RU2013120481A (ru) 2014-11-20
BR112013009004A8 (pt) 2017-12-26
MX2013004067A (es) 2013-07-29
SI2627328T1 (sl) 2017-01-31
US9186359B2 (en) 2015-11-17
HRP20161402T1 (hr) 2016-12-30
EP2627328B1 (en) 2016-09-14
JP2013539767A (ja) 2013-10-28
US20160058762A1 (en) 2016-03-03
CA2813648C (en) 2019-06-25
CA2813648A1 (en) 2012-04-19
US10632116B2 (en) 2020-04-28
PL2627328T3 (pl) 2017-03-31
WO2012048710A1 (en) 2012-04-19
AU2011316225B2 (en) 2016-05-19
CN103402514A (zh) 2013-11-20
JP5907975B2 (ja) 2016-04-26
RU2611376C2 (ru) 2017-02-21
CN103402514B (zh) 2016-01-13
KR101825972B1 (ko) 2018-02-06
CY1118314T1 (el) 2017-06-28
MX353625B (es) 2018-01-22
BR112013009004A2 (pt) 2016-07-05
DK2627328T3 (en) 2016-12-12
ES2602973T3 (es) 2017-02-23
LT2627328T (lt) 2016-11-25
HUE031661T2 (en) 2017-07-28
US20130252965A1 (en) 2013-09-26
CN105193809B (zh) 2019-07-16
RS55332B1 (sr) 2017-03-31
CN105193809A (zh) 2015-12-30
IL225758A0 (en) 2013-06-27
KR20130101545A (ko) 2013-09-13
AU2011316225A1 (en) 2013-04-18
EP2627328A1 (en) 2013-08-21
IL225758A (en) 2017-03-30

Similar Documents

Publication Publication Date Title
IL225758A0 (en) Preparations containing combinations of serotonin agonists and their uses
ZA201404787B (en) Substituted 4-phenyl-pyridines for the treatment of nk-1 receptor related diseases
IL227308A0 (en) Use of tlr receptor agonists for cancer treatment
IL226401A0 (en) Methods for treating disorders related to @fgfBA
KR102297388B9 (ko) 대사장애를 치료하기 위한 아커만시아의 용도
EP2522633A4 (en) DEVICE FOR HYDROGENING A BIOCOMPATIBLE SOLUTION
GB201410398D0 (en) Muscarinic m1 receptor agonists
EP2670746A4 (en) BICYCLIC HETEROARYL COMPOUNDS AS GPR119 RECEPTOR AGONISTS
GB201202773D0 (en) Compositions for treatment of skin disorders
PL2649068T3 (pl) Pochodne eteru oksazolilowo-metylowego jako agoniści receptora ALX
IL215660A0 (en) 5-ht4 receptor agonist compounds for treatment of cognitive disorders
IL225896A0 (en) Treatment of mecp-2 related disorders
EP2540721A4 (en) GHRELIN RECEPTOR AGONIST FOR DYSKRASY TREATMENT
EP2854810A4 (en) GHRELIN RECEPTOR AGONISTS FOR THE TREATMENT OF ACHLORHYDRIA
ZA201301718B (en) Heterocyclic compounds for treating or preventing disorders caused by reduced neurotransmission of serotonin,norephnephrine or dopamine
ZA201306734B (en) Controlled release pharmaceutical compositions of selective serotonin reuptake inhibitor
GB201006167D0 (en) Compounds for the treatment of metabolic disorders
IL233189A0 (en) New medical use of p75 receptor agonists
GB201006166D0 (en) Compounds for the treatment of metabolic disorders
HK1188927A (en) Combinations of serotonin receptor agonists for treatment of movement disorders
ZA201408672B (en) Use of ghrelin receptor inverse agonists or antagonists for treating sleep disorders
GB201118065D0 (en) Treatment of movement disorders
ZA201105273B (en) Controlled release pharmaceutical composition of non-ergoline dopamine agonist
GB201106154D0 (en) Compounds for the treatment of metabolic disorders
GB201106142D0 (en) Compounds for the treatment of metabolic disorders